Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19

Scandinavian Journal of Immunology

Volumn 46, Issue 5, 1997, Pages 452-458

  Klein, S C ^a   Boer, L H ^a   De Weger, R A ^a   De Gast, G C ^a   Bast, E J E G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MEDIATOR RELEASE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030663390     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-151.x     Document Type: Article

References (21)

1. Jenkins MK, Johnson JG. Molecules involved in T-cell costimulation. Curr Opin Immunol 1993;5:361-7.
2. Janeway CA Jr., Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-85.
3. Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM. G 19.4 (aCD3) × B43 (aCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4; 11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992;80:2826-34.
4. Haagen IA, van de Griend R, Clark M, Geerars A, Bast B, de Gast B. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (CD3 × CD19). Clin Exp Immunol 1992;90:368-75.
5. Haagen IA, Geerars AJ, de Lau WB et al. Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 1994;84:556-63.
6. Bohlen H, Hopff T, Manzke O et al. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993;82:1803-12.
7. de Gast GC, Haagen IA, van Houten AA et al. CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 1995;40:390-6.
8. de Gast GC, van Houten AA, Haagen IA et al. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J Hematotherapy 1995; 4:433-7.
9. Rosenfeld C, Goutner A, Choquet C et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature 1977;267:841-3.
10. Saxon A, Feldhaus J, Robins A. Single step separation of human T and B cells using AET treated SRBC rosettes. J Immunol Methods 1976;12:285-8.
11. Clark MR, Waldmann H. T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst 1997;79:1393-401.
12. Clark M, Bindon C, Dyer M et al. The improved lytic function and in vivo efficacy of monovalent monoclonal. Eur J Immunol 1989;19:381-8.
13. Haagen IA, Geerars AJ, de Lau WB, Bast BJ, de Gast BC. The efficacy of CD3 × CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repealed addition of BsAb and interleukin-2. Blood 1995;85:3208-12.
14. Bast RC Jr., de Fabritiis P, Lipton J et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985;45:499-503.
15. Johnson EA, Brown BWM. The Spearman estimator for serial dilution assays. Biometrics 1961;17:79-88.
16. Janssen RA, Mulder NH, The TH, de Leij L. The immunobiological effects of interleukin-2 in vivo. Cancer Immunol Immunother 1994;39:207-16.
17. Chatenoud L, Bach JF. Antigenic modulation - a major mechanism of antibody action. Immunology Today 1984;5:20-5.
18. Kroesen BJ, Buter J, Sleijfer DT et al. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2 Br J Cancer 1994;70:652-61.
19. Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T cell activation. J Immunol 1989;142:2230-6.
20. Ho AD, Maruyama M, Maghazachi A, Mason JR, Gluck S, Corringham RE. Soluble CD4, soluble CD8, soluble CD25, lymphopoieitic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood 1994;84:3550-7.
21. Yoneyama A, Nakahara K, Higashihara M, Kurokawa K. Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis. Br J Haematol 1995;89:47-54.